Trials / Completed
CompletedNCT00421707
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind, placebo-controlled, randomised crossover study to investigate the efficacy and safety of GW876008
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW876008 | |
| OTHER | Placebo |
Timeline
- Start date
- 2006-10-14
- Primary completion
- 2008-06-25
- Completion
- 2008-06-25
- First posted
- 2007-01-12
- Last updated
- 2018-01-31
- Results posted
- 2017-12-26
Locations
23 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00421707. Inclusion in this directory is not an endorsement.